The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, several authors have previously shown that the addition of ABT-737, an inhibitor to anti-apoptotic BCL-2 and BCL-XL, partially sensitized melanoma cells to BRAF inhibitors66,67.”
From Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies (2019) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605714 · Cited by 314
Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2007) · Modern Pathology · doi:10.1038/modpathol.3800750 · Cited by 202
Self-citation
Research works printed but not linked: 45
- Flaherty, 2010, New England Journal of Medicine, 363, 809, 10.1056/NEJMoa1002011 · DOI · Paper page
- 2009, Annals of Oncology, 20, vi35, 10.1093/annonc/mdp254 · DOI
- Smalley, 2010, Current opinion in investigational drugs (London, England : 2000), 11, 699
- Chapman, 2011, New England Journal of Medicine, 364, 2507, 10.1056/NEJMoa1103782 · DOI · Paper page
- Poulikakos, 2011, Cancer cell, 19, 11, 10.1016/j.ccr.2011.01.008 · DOI · Paper page
- Solit, 2011, New England Journal of Medicine, 364, 772, 10.1056/NEJMcibr1013704 · DOI · Paper page
- Montagut, 2008, Cancer Research, 68, 4853, 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
- Nazarian, 2010, Nature; Physical Science (London), 468, 973, 10.1038/nature09626 · DOI · Paper page
- Johansson, 2007, Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society, 20, 216, 10.1111/j.1600-0749.2007.00375.x · DOI · Paper page
- 2011, Clinical Cancer Research, 17, 721, 10.1158/1078-0432.CCR-10-2225 · DOI · Paper page
- 2011, Cancer Research, 71, 7137, 10.1158/0008-5472.CAN-11-1243 · DOI · Paper page
- Fedorenko, 2011, Biochemical pharmacology, 82, 201, 10.1016/j.bcp.2011.05.015 · DOI · Paper page
- 2008, PNAS, 105, 3041, 10.1073/pnas.0711741105 · DOI · Paper page
- Jiang, 2010, 1, e69, 10.1038/cddis.2010.48 · DOI
- Lee, 2010, 23, 820, 10.1111/j.1755-148X.2010.00763.x · DOI · Paper page
- Oltersdorf, 2005, Nature; Physical Science (London), 435, 677, 10.1038/nature03579 · DOI · Paper page
- van Delft, 2006, Cancer cell, 10, 389, 10.1016/j.ccr.2006.08.027 · DOI · Paper page
- Jiang, 2008, Cancer Research, 68, 6708, 10.1158/0008-5472.CAN-08-0349 · DOI · Paper page
- Keuling, 2009, 4, e6651, 10.1371/journal.pone.0006651 · DOI
- 2012, Clinical Cancer Research, 18, 783, 10.1158/1078-0432.CCR-11-1166 · DOI
- Jiang, 2007, Cancer Research, 67, 9750, 10.1158/0008-5472.CAN-07-2047 · DOI · Paper page
- Zhang, 1999, Cancer Research, 59, 2747
- Nguyen, 2001, Clinical Cancer Research, 7, 966s
- Smalley, 2006, Molecular Cancer Therapeutics, 5, 1136, 10.1158/1535-7163.MCT-06-0084 · DOI · Paper page
- 2008, 3, 1, 10.1517/17460441.3.1.1 · DOI · Paper page
- Haass, 2008, Clinical Cancer Research, 14, 230, 10.1158/1078-0432.CCR-07-1440 · DOI · Paper page
- Santiago-Walker, 2009, Skin pharmacology and physiology, 22, 114, 10.1159/000178870 · DOI
- Chou, 1984, Advances in enzyme regulation, 22, 27, 10.1016/0065-2571(84)90007-4 · DOI · Paper page
- 2007, Clinical Cancer Research, 13, 4934, 10.1158/1078-0432.CCR-07-0665 · DOI · Paper page
- Adams, 2007, Current opinion in immunology, 19, 488, 10.1016/j.coi.2007.05.004 · DOI · Paper page
- Youle, 2008, Nature reviews. Molecular cell biology, 9, 47, 10.1038/nrm2308 · DOI · Paper page
- Chen, 2007, Cancer Research, 67, 782, 10.1158/0008-5472.CAN-06-3964 · DOI · Paper page
- Lai, 2012, Melanoma research, 22, 244, 10.1097/CMR.0b013e328353eff2 · DOI
- 2003, Journal of Biological Chemistry, 278, 18811, 10.1074/jbc.M301010200 · DOI · Paper page
- Ewings, 2007, The EMBO Journal, 26, 2856, 10.1038/sj.emboj.7601723 · DOI · Paper page
- Dong, 2011, Oncogene, 30, 3716, 10.1038/onc.2011.87 · DOI
- Malik, 2011, Oncogene, 30, 3918, 10.1038/onc.2011.104 · DOI · Paper page
- 2010, The Journal of Cell Biology, 189, 83, 10.1083/jcb.200909166 · DOI · Paper page
- Zheng, 2009, Molecular cell, 33, 237, 10.1016/j.molcel.2008.12.026 · DOI · Paper page
- 2012, PNAS, 109, 2766, 10.1073/pnas.1104778108 · DOI · Paper page
- Weber, 2009, 2, 73, 10.1593/tlo.08223 · DOI
- Reuland, 2011, 6, e24294, 10.1371/journal.pone.0024294 · DOI
- Risberg, 2011, 6, e24012, 10.1371/journal.pone.0024012 · DOI
- Shoemaker, 2008, Clinical Cancer Research, 14, 3268, 10.1158/1078-0432.CCR-07-4622 · DOI · Paper page
- 2010, PNAS, 107, 10967, 10.1073/pnas.1005256107 · DOI · Paper page
Cited by
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 80
Metadata
- Authors
- Wroblewski, D., Mijatov, B., Mohana-Kumaran, N., Lai, F., Gallagher, S. J., Haass, N. K., Zhang, X. D., & Hersey, P.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-20
- Volume
- 34
- Issue
- 2
- Pages
- 237-247
- ISSN
- 0143-3334
- 1460-2180
- Cited by
- 57
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. https://app.cochat.ai/papers/10.1093/carcin/bgs330
- The paper
- Wroblewski, D., Mijatov, B., Mohana-Kumaran, N., Lai, F., Gallagher, S. J., Haass, N. K., Zhang, X. D., & Hersey, P. (2013). The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis. https://doi.org/10.1093/carcin/bgs330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.